Dissociation of thrombin's substrate interactions using site-directed mutagenesis

被引:11
作者
Leung, LLK [1 ]
Hall, SW [1 ]
机构
[1] Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA
关键词
D O I
10.1016/S1050-1738(00)00047-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thrombin is an allosteric enzyme that interacts with multiple procoagulant substrates such as specific clotting factors and cell surface thrombin receptors, as well as the anticoagulant substrate protein C. Functional mapping of thrombin's interactions with its various substrates has been carried out using a collection of thrombin mutants generated by systematic alanine scanning mutagenesis. A thrombin mutant, E229K, has been identified that has essentially lost all of its procoagulant properties while retaining its ability to activate protein C, thus functioning as an anticoagulant in vitro and in vivo. It is also found that specific and distinct domains are involved in thrombin's interaction with thrombomodulin (TM) and the subsequent activation by the thrombin/TM complex of protein C and the thrombin-activatable fibrinolysis inhibitor (TAFI). (Trends Cardiovasc Med 2000;10:89-92). (C) 2000, Elsevier Science Inc.
引用
收藏
页码:89 / 92
页数:4
相关论文
共 25 条
[1]   TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex [J].
Bajzar, L ;
Morser, J ;
Nesheim, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (28) :16603-16608
[2]   PURIFICATION AND CHARACTERIZATION OF TAFI, A THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR [J].
BAJZAR, L ;
MANUEL, R ;
NESHEIM, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) :14477-14484
[3]  
Bajzar L, 1999, BLOOD, V94, p22A
[4]   Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties [J].
Boffa, MB ;
Wang, W ;
Bajzar, L ;
Nesheim, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (04) :2127-2135
[5]   Coagulation-dependent inhibition of fibrinolysis: Role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma [J].
Broze, GJ ;
Higuchi, DA .
BLOOD, 1996, 88 (10) :3815-3823
[6]   THE NA+ BINDING-SITE OF THROMBIN [J].
DICERA, E ;
GUINTO, ER ;
VINDIGNI, A ;
DANG, QD ;
AYALA, YM ;
WUYI, M ;
TULINSKY, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (38) :22089-22092
[7]  
Esmon CT, 1999, THROMB HAEMOSTASIS, V82, P251
[8]   AN UPDATE ON CLINICAL AND BASIC ASPECTS OF THE PROTEIN-C ANTICOAGULANT PATHWAY [J].
ESMON, CT ;
SCHWARZ, HP .
TRENDS IN CARDIOVASCULAR MEDICINE, 1995, 5 (04) :141-148
[9]   CONVERSION OF THROMBIN INTO AN ANTICOAGULANT BY PROTEIN ENGINEERING [J].
GIBBS, CS ;
COUTRE, SE ;
TSIANG, M ;
LI, WX ;
JAIN, AK ;
DUNN, KE ;
LAW, VS ;
MAO, CT ;
MATSUMURA, SY ;
MEJZA, SJ ;
PABORSKY, LR ;
LEUNG, LLK .
NATURE, 1995, 378 (6555) :413-416
[10]   Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains [J].
Hall, SW ;
Nagashima, M ;
Zhao, L ;
Morser, J ;
Leung, LLK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (36) :25510-25516